MedTrace Logo

Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics

NCT06260410 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-04-22

No results posted yet for this study

Summary

This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.

Conditions

  • Prostate Cancer Metastatic

Interventions

DIAGNOSTIC_TEST

Blood draw for ctDNA and circulating tumor cell collection.

During routine blood sample collection, additional blood will be drawn for analysis of ctDNA and to collect Circulating Tumor Cells.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-20
Primary Completion
2027-02-01
Completion
2027-02-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06260410 on ClinicalTrials.gov